Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE-lung: Amivantamab, Lazertinib Plus Bevacizumab in EGFR-mutant Advanced NSCLC
NCT05601973Phase 2Active, not recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of amivantamab and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFR-TKI at 12 weeks. Started Mar 2023; status: active, not recruiting.
02
Drugs
amivantamabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05601973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601973.